Advaxis, Inc.
Advaxis Applies for Approximately $1.0 Million Worth of Grants from the National Institute of Health
Published in Cancer Weekly, May 12th, 2009
“The current stimulus package has significantly increased funding for NIH grants,” commented Advaxis CEO Thomas A. Moore. “We have been the fortunate recipient of a multitude of NIH grants. We believe the proposals hold great promise.” About Advaxis Vaccines HER-2 Antigen: The Company’s HER-2 vaccine is based upon a chimeric assembly of many internal and external immune epitopes found to be effective anti-cancer targets. Although never before used...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2009-05-12)
More Articles from Cancer Weekly
- American Institute of Physics
Simulated gene therapy - Angiogenesis
Researchers from Musashino University report on findings in angiogenesis - Antiretrovirals
New antiretrovirals findings from New York University published - Ardea Biosciences, Inc.
Ardea Biosciences and Bayer HealthCare Enter into Global Agreement Focused on the Development of MEK Inhibitors for the Treatment of Cancer - Array BioPharma Inc.
Array BioPharma’s ARRY-520 Demonstrates Significant Activity in Hematological and Taxane-Resistant Tumors - Breast Cancer
Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
